Chronic heart failure - Impact of the condition on patients and the healthcare system in the Czech Republic: A retrospective cost-of-illness analysis

被引:4
|
作者
Pavlusova, Marie [1 ,2 ]
Klimes, Jiri [3 ,4 ]
Spinar, Jindrich [1 ,2 ]
Zeman, Kamil [5 ]
Jarkovsky, Jiri [6 ]
Benesova, Klara [6 ]
Miklik, Roman [1 ,2 ]
Pohludkova, Ludmila [5 ]
Felsoci, Marian [1 ,2 ]
Vesela, Vera [3 ]
Blahovcova, Michaela [3 ]
Dostal, Filip [3 ]
Vonka, Richard [3 ]
Parenica, Jiri [1 ,2 ]
机构
[1] Univ Hosp Brno, Dept Cardiol, Brno, Czech Republic
[2] Masaryk Univ, Med Fac, Brno, Czech Republic
[3] Novartis Sro, Prague, Czech Republic
[4] Charles Univ Prague, Fac Pharm Hradec Kralove, Prague, Czech Republic
[5] Hosp Frydek Mistek, Dept Internal Med, Frydek Mystek, Czech Republic
[6] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno, Czech Republic
关键词
Chronic heart failure; Hospitalization costs; Cost-of-illness;
D O I
10.1016/j.crvasa.2018.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The number of patients with heart failure is steadily increasing, as are the costs of their treatment. Nearly 70% of the costs associated with the treatment of heart failure are direct medical costs, and 70-80% of these are spent on hospitalizations. The aim of our study is to describe the all-cause hospitalization costs of patients with chronic heart failure (chronic HF) from the perspective of the healthcare system in the Czech Republic. Methods: In total, 1274 consecutively collected patients discharged in a stable condition from hospitalization for acute heart failure (= index hospitalization) from 2006 to 2012 were followed-up for 2 years. Their all-cause mortality and all-cause hospitalizations were retrospectively evaluated. The in-patient costs were calculated based on the relative weights of DRG codes for particular hospitalization events and on the basic DRG tariff for 2013 (CZK 28,898). Results: At the end of the 2-year follow-up, a total of 1511 hospitalizations were recorded. A total of 31.8% of patients survived without any hospitalization, 32.1% of patients survived with at least one hospitalization, and 36.1% of patients died. Re-hospitalizations for acute heart failure accounted for 31.2% of all cases. The average cost for one chronic HF patient hospitalized for any reason was CZK 85,414; the cost for acute heart failure re-hospitalization was CZK 31,320 during the 2-year follow-up period. The cost of all-cause hospitalizations within the first year after the index hospitalization was higher compared to the cost during the second year (CZK 58,528/year vs. CZK 23,082/year). As the estimated number of chronic HF patients is 230,000 (data from the Institute of Health Information and Statistics of the Czech Republic), we can calculate the total cost of all-cause hospitalizations of chronic HF patients to be approximately CZK 7.98 billion per year in the Czech Republic. Conclusion: The data from clinical practice confirm that patients with chronic HF discharged from acute heart failure hospitalization are at high risk of death and/or subsequent hospitalization. The average annual costs for all-cause hospitalizations of CHS patients within the first and second years are CZK 58,528 and CZK 23,082 per patient, respectively. The costs attributed to all-cause hospitalization care of chronic HF patients can be estimated as approximately 7.7% of all annual inpatient expenses of health insurance companies and 2.7% of total healthcare expenditures in the Czech Republic. (C) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:E224 / E233
页数:10
相关论文
共 50 条
  • [1] CHRONIC HEART FAILURE (CHF) IN THE CZECH REPUBLIC: COST-OF-ILLNESS ANALYSIS & DISEASE BURDEN BASED ON AHEAD REGISTRY DATA MINING
    Spinar, J.
    Parenica, J.
    Klimes, J.
    Vesela, V.
    Blahovcova, M.
    Dostal, F.
    Vonka, R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A610 - A610
  • [2] TREATMENT OF PATIENTS WITH MODERATE AND SEVERE PSORIASIS - COST-OF-ILLNESS IN THE CZECH REPUBLIC
    Petrikova, A.
    Klimes, J.
    Dolezal, T.
    Marinov, L.
    Petrova, G.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A305 - A306
  • [3] A SYSTEMATIC REVIEW OF COST-OF-ILLNESS STUDIES IN CHRONIC HEART FAILURE
    Lesyuk, W.
    Kriza, C.
    Kolominsky-Rabas, P. L.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A484 - A484
  • [4] Cost-of-illness Analysis of Patients with Chronic Hand Eczema in Routine Care in Germany: Focus on the Impact of Occupational Disease
    Diepgen, Thomas L.
    Purwins, Sandra
    Posthumus, Jan
    Kuessner, Daniel
    John, Swen M.
    Augustin, Matthias
    [J]. ACTA DERMATO-VENEREOLOGICA, 2013, 93 (05) : 538 - 543
  • [5] Productivity Loss in Patients With Chronic Diseases: A Pooled Economic Analysis of Hungarian Cost-of-Illness Studies
    Rashdan, Omar
    Brodszky, Valentin
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 22 : 75 - 82
  • [6] The economic impact of patients with heart failure on the Lebanese healthcare system
    Tatari, Souzan
    Soubra, Lama
    Tamim, Hani
    Akhras, Kassem
    Kabbani, Samer
    [J]. ESC HEART FAILURE, 2015, 2 (03): : 178 - 183
  • [7] COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
    Ondrackova, B.
    Miklik, R.
    Parenica, J.
    Spinar, J.
    Sulcova, A.
    Tomcikova, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A336 - A336
  • [8] Registry based analysis of cost-of-illness study among stage C heart failure patients at Hospital Queen Elizabeth II, Sabah, Malaysia
    Shafie, Asrul Akmal
    Tan, Yui Ping
    Liau, Siow Yen
    Yang, Su Lan
    Liew, Houng Bang
    Chaiyakunapruk, Nathorn
    [J]. HEALTH POLICY AND TECHNOLOGY, 2019, 8 (01) : 51 - 60
  • [9] A cost effectiveness analysis of spironolactone in the management of patients with severe chronic heart failure (CHF) in the Irish healthcare setting
    Tilson, L
    McGowan, B
    Barry, M
    Ryan, M
    [J]. VALUE IN HEALTH, 2002, 5 (06) : 485 - 485
  • [10] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE IN DOMINICAN REPUBLIC
    Ordonez, J.
    Cruz, L.
    Feliz, E.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S383 - S383